Cas 512785-10-3,Butanoic acid, 4-oxo-4-[[(1S)-1-phenylethyl]amino]-3-[[(phenylmethoxy)carbonyl]amino] -, 1,1-dimethylethyl ester, (3R)-

512785-10-3

Post Buying Request

Basic information

Product Name: Butanoic acid, 4-oxo-4-[[(1S)-1-phenylethyl]amino]-3-[[(phenylmethoxy)carbonyl]amino] -, 1,1-dimethylethyl ester, (3R)-
Synonyms:
CAS NO:512785-10-3
Molecular Formula: C24H30N2O5
Molecular Weight: 426.513
EINECS: N/A
Product Categories: N/A

Chemical Properties

Melting Point: N/A
Boiling Point: N/A
Flash Point: N/A
Appearance: N/A
Density: N/A
Refractive Index: N/A
Storage Temp.: N/A
Solubility: N/A
CAS DataBase Reference: Butanoic acid, 4-oxo-4-[[(1S)-1-phenylethyl]amino]-3-[[(phenylmethoxy)carbonyl]amino] -, 1,1-dimethylethyl ester, (3R)-(CAS DataBase Reference)
NIST Chemistry Reference: Butanoic acid, 4-oxo-4-[[(1S)-1-phenylethyl]amino]-3-[[(phenylmethoxy)carbonyl]amino] -, 1,1-dimethylethyl ester, (3R)-(512785-10-3)
EPA Substance Registry System: Butanoic acid, 4-oxo-4-[[(1S)-1-phenylethyl]amino]-3-[[(phenylmethoxy)carbonyl]amino] -, 1,1-dimethylethyl ester, (3R)-(512785-10-3)

Safety Data

Hazard Codes: N/A
Statements: N/A
Safety Statements: N/A
WGK Germany:
RTECS:
HazardClass: N/A
PackingGroup: N/A
Hazardous Substances Data: 512785-10-3(Hazardous Substances Data)

Suppliers
Usage
Upstream product
Downstream Products
Article

512785-10-3 Suppliers

Recommended suppliers

512785-10-3 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 512785-10-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 5,1,2,7,8 and 5 respectively; the second part has 2 digits, 1 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 512785-10:
(8*5)+(7*1)+(6*2)+(5*7)+(4*8)+(3*5)+(2*1)+(1*0)=143
143 % 10 = 3
So 512785-10-3 is a valid CAS Registry Number.

512785-10-3Upstream product

512785-10-3Downstream Products

512785-10-3Relevant academic research and scientific papers

COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY

-

Page/Page column 57; 58, (2019/04/11)

Compounds, and compositions, methods, and uses thereof, are described herein for treating brain injuries.

BETA-LACTAMYL VASOPRESSIN V1A ANTAGONISTS

-

Paragraph 0115; 0119, (2018/02/04)

Novel 2-(azetidin-2-on-1-yl)alkanedioic acid derivatives and 2-(azetidin-2-on-1-yl)alkoxyalkanoic acid derivatives are described for use in the treatment of disease states responsive to antagonism of the vasopressin V1a receptor.

METHODS FOR TREATING POST TRAUMATIC STRESS DISORDER

-

Page/Page column 50, (2012/01/15)

Compounds and compositions are described herein for treating post tramatic stress disorder.

BETA-LACTAM CANNABINOID RECEPTOR MODULATORS

-

Page/Page column 88-89, (2008/06/13)

Described herein are substituted 2-(azetidin-2-on-l-yl)alkanoic acids, alkanedioic acids and 2-hydroxyalkyl alkanoic acids, and 2-acyl alkanoic acids, and derivatives thereof, that are capable of modulating activity at the cannabinoid-1 (CBl) and/or canna

Azetidinones as vasopressin V1a antagonists

Guillon, Christophe D.,Koppel, Gary A.,Brownstein, Michael J.,Chaney, Michael O.,Ferris, Craig F.,Lu, Shi-fang,Fabio, Karine M.,Miller, Marvin J.,Heindel, Ned D.,Hunden, David C.,Cooper, Robin D.G.,Kaldor, Stephen W.,Skelton, Jeffrey J.,Dressman, Bruce A.,Clay, Michael P.,Steinberg, Mitchell I.,Bruns, Robert F.,Simon, Neal G.

, p. 2054 - 2080 (2007/10/03)

The azetidinone LY307174 (1) was identified as a screening lead for the vasopressin V1a receptor (IC50 45 nM at the human V1a receptor) based on molecular similarity to ketoconazole (2), a known antagonist of the luteinizing hormone releasing h

β -LACTAMYL VASOPRESSIN V2 ANTAGONISTS

-

Page/Page column 66-67, (2010/11/28)

β-lactamyl alkanoic acids and pharmaceutical compositions thereof are described. Methods for treating various diseases and disease states using one or more β-lactamyl alkanoic acids are also described. Substituted 2-(azetidin-2-on-l-yl)alkanedioic acids,

HYDROXY AND KETO-SUBSTITUTED β-LACTAMYL ALKANEDIOIC ACIDS

-

Page/Page column 52, (2010/11/28)

3-Hydroxy and 3-keto substituted 2-(azetidin-2-on-l-yl)alkanedioic acids, and analogs and derivatives thereof are described. Methods for using 3-hydroxy and 3-keto substituted 2-(azetidin-2-on-l-yl)alkanedioic acids, and analogs and derivatives thereof, i

BETA-LACTAMYLALKANOIC ACIDS FOR TREATING PREMENSTRUAL DISORDERS

-

Page/Page column 26, (2008/06/13)

0-lactamyl alkanoic acids are described. Methods for treating various premenstrual disorders using or more β-lactamyl alkanoic acids are also described.

3-SUBSTITUTED β-LACTAMYL VASOPRESSIN V1A ANTAGONISTS

-

Page/Page column 44-45, (2008/06/13)

Novel 2-(azetidin-2-on-1-yl)alkanedioic acids and derivatives thereof are described. Methods for using 2-(azetidin-2-on-l-yl)alkanedioic acids and derivatives thereof in the treatment of disease states responsive to antagonism of the vasopressin V1a

Post a RFQ

Cas No.:

Product Name:

Quantity:

Email:

Company name:

Valid Period:

Detailed Requirements:

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

What can I do for you?
Get Best Price

Get Best Price for 512785-10-3